Background {#Sec1}
==========

Ritonavir is a potent inhibitor of the cytochrome P450 enzyme CYP3A4 that can lead to multiple drug--drug interactions. Systemic complications resulting from inhaled corticosteroids like fluticasone are rare but when used concomitantly with ritonavir can lead to iatrogenic Cushing syndrome and adrenal suppression. It is important to be aware of this interaction to avoid serious and potentially fatal complications. We report a case of iatrogenic Cushing syndrome, adrenal insufficiency and severe osteoporosis due to the potentiated systemic glucocorticoid effect of inhaled fluticasone by ritonavir in a patient with human immunodeficiency virus (HIV).

Case presentation {#Sec2}
=================

A 57 year old Caucasian male with HIV infection since 1986 was evaluated in 4/2010 for recurrent rib fractures following trivial stresses such as coughing. His highly active antiretroviral therapy (HAART) since 2006 consisted of lamivudine 150 mg twice daily, zidovudine 300 mg twice daily and lopinavir--ritonavir 400--100 mg twice daily. Fluticasone/salmeterol 250/50 mcg one puff twice daily was introduced in 9/2007 for severe COPD. Other medical conditions included coronary artery disease, dyslipidemia and GERD treated with aspirin, clopidogrel, omeprazole, pravastatin and niacin. Physical examination showed centripetal adiposity, multiple ecchymoses and pronounced pink abdominal and inguinal striae (Fig. [1](#Fig1){ref-type="fig"}). Weight had increased by 5 kg from baseline weight. There was palpable rib tenderness. The reminder of the physical examination was unremarkable. Of note his AIDS clinician mistook his phenotypic changes to be those of AIDS related lipodystrophy. These same changes eluded his PCP.Fig. 1Centripetal adiposity, multiple ecchymoses and pronounced pink abdominal and inguinal striae

Chest radiographs confirmed numerous rib fractures (Fig. [2](#Fig2){ref-type="fig"}). Lumbar and proximal femur bone mineral density (BMD) T-scores were −5.2 and −3.4 respectively. Complete blood count, renal and hepatic function, electrolytes, calcium, phosphate, intact parathyroid hormone, 25-OH-VitD, prolactin, serum and urine protein electrophoresis and serum free light chains were normal. His random morning serum cortisol was 0.5 mcg/dl (normal 4--24 mcg/dL) and 1 h after 250 mcg intravenous cosyntropin stimulation was 7.1 mcg/dL (expected \>20 mcg/dL) consistent with adrenal insufficiency. A 24 h urine free cortisol was \<7.2 mcg, late night salivary cortisol was \<10 ng/dL (\<100 ng/dL) and dehydroepiandrosterone sulphate was \<30 mcg/dL (40--310 mcg/dL). Serum ACTH was 32 pg/mL (normal 0--46 pg/mL). A 24 h urinary synthetic glucocorticoid screen was only positive for a fluticasone 17-β-carboxylic acid value of 243 pg/mL. Pituitary magnetic resonance imaging (MRI) was normal. Serum and 24-h urine N-telopeptides were 19.2 nmol BCE (5.4--24 nmol BCE) and 23 nmol/mmol BCE (21--66 nmol/mmol BCE) respectively. Total and bone specific alkaline phosphatase were 73 IU/L (20--71 IU/L) and 151 IU/L (40--125 IU/L) respectively.Fig. 2Chest X-ray showing numerous rib fractures

The patient was diagnosed with iatrogenic Cushing syndrome and adrenal suppression secondary to the potentiated systemic glucocorticoid effect of inhaled fluticasone by ritonavir. Fluticasone was continued as the patient reported significant improvement in his COPD symptoms. Ritonavir boosted protease inhibitor therapy was discontinued and he was placed on Raltegravir which is not known to inhibit CYP3A4. His HIV viral load continues to be undetectable and 2 years after change in antiretroviral therapy his CD4 count is 624. He was placed on physiological doses of hydrocortisone at 20 mg per day and has gradually tapered to 5 mg/day of hydrocortisone 1 year from presentation. His severe osteoporosis was treated with subcutaneous teriparatide, appropriate calcium and vitamin D supplementation and a physical therapy.

Serial basal and stimulated cortisol levels are reported in Table [1](#Tab1){ref-type="table"}. His cushingoid features improved by 3 months (Fig. [3](#Fig3){ref-type="fig"}). One year after initiating osteoporosis treatment lumbar spine BMD improved from 0.530 to 0.932 gm/cm^2^ (+75.8 %) and total hip BMD from 0.681 to 0.761 gm/cm~2~ (+11.2 %). These BMD gains are significantly greater than those reported for lumbar spine (11 %) and total hip (5.2 %) in patients with glucocorticoid induced osteoporosis treated with teriparatide (Saag et al. [@CR18]). Follow up BMD at the completion of teriparatide treatment is shown in Table [2](#Tab2){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}. The patient has had no further fractures.Table 1Basal and stimulated cortisol levelsBasal cortisol (mcg/dL)1 h post ACTH cortisol level (mcg/dL)At diagnosis0.57.12 months2.5--9 months3.31812 months8.323.624 months722.5Fig. 3Markedly improved abdominal and inguinal striae as well as the ecchymotic lesionsTable 2BMD improvement after withdrawal of ritonavir and treatment with teriparatideBMD in gm/cm^2^ (T-score)L-SpineTotal hip (mean)Femoral neck (mean)At diagnosis0.530 (−5.7)0.681 (−2.9)0.589 (−3.7)12 months0.932 (−2.4)0.761 (−2.4)0.694 (−2.9)24 months1.065 (−1.3)0.825 (−1.9)0.734 (−2.6)36 months1.139 (−0.7)0.867 (−1.6)0.767 (−2.3)Fig. 4DXA trend after withdrawal of ritonavir and treatment with teriparatide along with depiction of improved trabecular bone scores

Discussion {#Sec3}
==========

A search of published English language literature using the keywords ritonavir, protease inhibitors, fluticasone, inhaled corticosteroids, Cushing's syndrome and adrenal suppression revealed a total of 11 pediatric and 26 adult cases of iatrogenic Cushing's syndrome and adrenal suppression from concomitant fluticasone and ritonavir therapy. 3 of 24 adult cases were secondary to intranasal fluticasone preparations and rest was from inhaled fluticasone. Fluticasone dose ranged from 500 to 2000 mcg/day in adult patients and 200--1000 mcg/day in pediatric patients. Ritonavir in both low doses "boosted" and in high doses was associated with significant interaction (Table [3](#Tab3){ref-type="table"}).Table 3Review of literature and showing the cases of iatrogenic Cushing's syndrome and adrenal suppression from concomitant fluticasone and ritonavir therapyAuthorsAgeRTV dose (mg/day)ICS dose (mcg/day)Duration^a^InterventionMahlab-Guri and Asher ([@CR35]) Case 112 F200Fluticasone 2006 monthsFluticasone replaced by montelukast Case 255 F200Fluticasone 10003 weeksFluticasone replaced by budesonide Case 365 F200Fluticasone 5006 monthsFluticasone discontinuedKaviani et al. ([@CR36]) Case 160 MNAFluticasone 12002 yearsFluticasone discontinuedKedem et al. ([@CR37]) Case 1FNANAUNKFluticasone and budesonide discontinuedRitonavir dose decreasedSamaras et al. ([@CR33]) Case 143 M200Fluticasone 5002 yearsFluticasone discontinued Case 243 M100Fluticasone 100018 monthsFluticasone discontinued Case 353 M200Fluticasone 10002 yearsFluticasone discontinued Case 449 M200Fluticasone 10006 weeksPI discontinued Case 543 M200Fluticasone 5004 monthsFluticasone discontinued Case 650 M100Fluticasone 10002 monthsFluticasone discontinuedNocent et al. ([@CR38]) Case 138 MNAFluticasone 20001.5 monthsFluticasone replaced with beclomethasoneLeitman et al. ([@CR39]) Case 149 MNAFluticasone 1000UNKFluticasone dose reducedValin et al. ([@CR31]) Case 165 FNAFluticasone 5006 monthsFluticasone discontinued Case 266 MNAFluticasone 5001 monthFluticasone discontinued Case 366 MNAFluticasone 5002 yearsFluticasone discontinued Case 429 MNAFluticasone 20001 monthFluticasone discontinued PI replaced with nelfinavirJinno and Goshima ([@CR40]) Case 160 MNAFluticasone NA18 monthsFluticasone discontinuedGillett et al. ([@CR41]) Case 127 F200Fluticasone 100010 weeksFluticasone discontinuedSoldatos et al. ([@CR42]) Case 166 M200Fluticasone 10004 monthsFluticasone dose decreased Case 266 M200Fluticasone 10006 monthsFluticasone replaced with budesonideRouanet et al. ([@CR34]) Case 144 M266.4Fluticasone 20002 monthsFluticasone discontinuedGupta and Dubé ([@CR32]) Case 145 M800Fluticasone 8805 monthsFluticasone taperedClevenbergh et al. ([@CR43]) Case 133 M200Fluticasone 10005 monthsFluticasone discontinuedChen et al. ([@CR44]) Case 132 MFluticasone 4005 monthsFluticasone discontinued Case 239 MFluticasone 80018 monthsFluticasone discontinuedHillebrand-Haverkort et al. ([@CR46]) Case 130 M1200Fluticasone 2005 monthsRTV replaced by NVPArrington-sanders et al. ([@CR28]) Case 111.4 F133Fluticasone 220Fluticasone and PI discontinued Case 220.9 M100Fluticasone 200Fluticasone discontinued Case 316.8 M200Fluticasone 250Stopped all medications Case 49.5 M133Fluticasone 220Fluticasone discontinued Case 51.8 F60Fluticasone 220Fluticasone discontinuedJohnson et al. ([@CR45]) Case 112 F134Fluticasone 5002 monthsRTV/LPV D/C Case 215 F200Fluticasone 100013 weeksFluticasone dose decreasedPessanha et al. ([@CR47]) Case 116 FNAFluticasone 5003 monthsRTV replaced by EFVSt Germain et al. ([@CR30]) Case 114 F100Fluticasone 5002 weeksFluticasone discontinuedRTV/ATV with heldBhumbra et al. ([@CR48]) Case 19 M108Fluticasone 4402 monthsFluticasone discontinuedMometasone 10011 monthsMometasone discontinuedle Roux et al. ([@CR29]) Case 147 MBudesonide 1600Budesonide discontinuedSagir et al. ([@CR49]) Case 148 MBudesonide 900019 daysBudesonide discontinued*RTV* ritonavir, *LPV* lopinavir, *ICS* inhaled corticosteroids, *EFV* efavirenz, *PI* protease inhibitors, *ATV* atazanavir, *NA* not available, *UNK* unknown, *NVP* nevirapine^a^Duration until onset of first symptoms

Combination anti-retroviral therapy, particularly the introduction of protease inhibitors has revolutionized HIV therapy and changed once a fatal disease to a chronic condition (Palella et al. [@CR16]). Ritonavir is a potent inhibitor of cytochrome P450 (CYP) 3A4 isozymes and significantly increases the concentration of drugs primarily eliminated by CYP3A metabolism such as macrolides, azoles, protease inhibitors and corticosteroids (Hsu et al. [@CR7]; Von Moltke et al. [@CR25]). This property of ritonavir is used to therapeutic advantage in ritonavir boosted protease inhibitor regimens and has decreased the pill burden and treatment failures and improved compliance with therapy (Thompson et al. [@CR20]).

With 30 % estimated prevalence of bronchial hyperactivity (Poirier et al. [@CR17]), HIV infected men who smoke are frequently exposed to inhaled corticosteroid therapy. To reduce airway inflammation treatment guidelines for asthma and chronic obstructive airway disease (COPD) recommend the routine use of inhaled corticosteroid alone or in combination with long acting bronchodilators (National Asthma Education and Prevention Program [@CR14]; Vestbo et al. [@CR24]). Fluticasone is a potent glucocorticoid commonly used in reactive airway disease. Compared with other available inhaled steroids, it has high glucocorticoid receptor binding affinity, is highly lipophilic, a large volume of distribution (318 L) (Wuerthwein et al. [@CR27]; Mackie et al. [@CR11]) and a longer elimination half-life (t~1/2~ 7--8 h). Less than 1 % of swallowed fluticasone is bioavailable due to its high first pass metabolism and rapid metabolism in liver by CYP3A4 enzyme system and conversion to inactive 17 B-carboxylic acid derivative (Harding [@CR5]). Concomitant use of fluticasone with potent CYP3A4 inhibitors such as ritonavir can lead to systemic accumulation of fluticasone and suppression of hypothalamic pituitary adrenal (HPA) axis. Ritonavir increased the area under concentration--time curve (AUC) of serum fluticasone by 350-fold in healthy volunteers (Laboratories [@CR1]). For this reason manufactures and the FDA recommend against routine use of combination of ritonavir and fluticasone unless benefits outweigh risks.

Fluticasone has been reported to cause greater dose related adrenal suppression when compared with budesonide, triamcinolone acetonide or beclomethasone dipropionate (Lipworth [@CR10]) even in the absence of CYP3A4 inhibitors like ritonavir. In a recent meta-analysis of 732 subjects with asthma, fluticasone in small to medium doses (50--500 mcg/day) alone showed minimal effect on adrenal function (Masoli et al. [@CR13]). In another prospective, non-randomized, open-label, cross sectional study, investigators found that patients taking high doses of fluticasone (\>880 mcg per day) for longer duration had abnormal adrenal function (White et al. [@CR26]).

Iatrogenic Cushing syndrome results from prolonged exposure to high doses of glucocorticoids. The vast majority of these cases result from administration of oral or parenteral glucocorticoids (Newell-Price et al. [@CR15]). Typical features include weight gain, central obesity, dorsocervical hump, moon face, facial plethora, thin skin, easy bruising, abdominal striae, hirsutism, proximal myopathy, osteopenia, glucose intolerance, hypertension, nephrolithiasis and psychiatric manifestations such as depression and psychosis (Newell-Price et al. [@CR15]). Osteoporosis is common and tends to involve trabecular bone resulting in an increased risk of fracture within 3 months of daily exposure (van Staa et al. [@CR21], [@CR22], [@CR23]).

Pituitary production of corticotropin (ACTH) will be suppressed by exogenous steroids, which leads to atrophy of the adrenal cortex and adrenal insufficiency. Diagnosis is confirmed by low early morning serum cortisol levels and subnormal response to standard ACTH stimulation test. An early morning serum cortisol levels \<3 mcg/dL (80 nmol/L) strongly suggests adrenal insufficiency, whereas levels \>15 mcg/dL (415 nmol/L) predicts a normal response of serum cortisol to ACTH stimulation test (Hagg et al. [@CR4]; Le Roux et al. [@CR8]). Patients with low or equivocal serum cortisol levels in whom adrenal insufficiency is suspected should undergo standard or low dose synthetic ACTH (Cosyntropin) stimulation test. Suboptimal response to Cosyntropin stimulation test is diagnostic of adrenal insufficiency. Simultaneous measurement of plasma ACTH helps in differentiation of primary from secondary or tertiary adrenal insufficiency. ACTH levels tend to be higher than normal in primary adrenal insufficiency whereas low or low normal in patients with secondary and tertiary adrenal insufficiency. Corticotropin-releasing hormone (CRH) test further differentiate secondary from tertiary adrenal insufficiency (Schulte et al. [@CR19]).

Human immunodeficiency virus associated lipodystrophy shares several morphological features and should be differentiated from Cushing Syndrome. Weight gain, central adiposity, dorsocervical hump, insulin resistance, osteopenia, dyslipidemia are common and are associated with ART therapy (Lichtenstein [@CR9]; Dube et al. [@CR3]; Carr and Cooper [@CR2]). Presence of facial plethora, cutaneous striae, and proximal myopathy differentiates it from Cushing syndrome and should prompt physicians to evaluate for HPA axis suppression. Sudden withdrawal of from steroid therapy has a potential to develop catastrophic adrenal crisis. Replacement with physiological doses of prednisone 5--7.5 mg a day, hydrocortisone 15--20 mg a day or equivalent should be initiated. Measurement of morning cortisol levels every 4--6 weeks serves as screening test for recovery of adrenal function. Morning serum cortisol level less than 3 mcg/dL indicates the need for continued replacement therapy, whereas a value greater than 20 mcg/dL indicates recovered HPA axis. Patients with morning cortisol levels between 3 and 20 mcg/dL will need further studies like Cosyntropin stimulation test or overnight metyrapone test. It may take 9--12 months for the recovery of adrenal function (Hopkins and Leinung [@CR6]).

In patients with iatrogenic Cushing syndrome and adrenal insufficiency secondary to the interaction between ritonavir and fluticasone available options include, replacing ritonavir with another antiretroviral agent, replacing fluticasone with another less potent steroid or leukotriene antagonists or long acting anticholinergic agent such as tiotropium. In the SPIRAL study, Raltegravir demonstrated the non-inferior efficacy and improved lipid profile when ritonavir boosted protease inhibitor therapy was replaced by Raltegravir (Martinez et al. [@CR12]). The latter approach was taken in our patient with favourable outcome.

Conclusions {#Sec4}
===========

Despite the recommendations against concomitant use of fluticasone and ritonavir several reports of Cushing syndrome and adrenal suppression are being reported. We believe physicians treating HIV infected patients must be aware of potential interaction of antiretroviral therapy and drugs used to treat associated co-morbidities. When iatrogenic Cushing syndrome is suspected, prompt evaluation and discontinuation of offending medication will prevent potentially fatal complications.

Consent {#Sec5}
=======

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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